A recent study suggests that patients who come off blockbuster slimming jabs like semaglutide or tirzepatide tend to recover shed pounds much more quickly than those who halt conventional lifestyle plans.
Published data in a leading health publication points out that while overweight people often shed a large proportion of their total mass while undergoing treatment, the weight returns at an average rate of nearly a kilo each month once they quit.
"Individuals purchasing such treatments need to be cognizant of the potential of rapid weight regain when the therapy ends," cautioned researcher Dr. Susan Jebb.
Such speed of recovery means a return to original weight in about one and a half years.
Weighing Therapies
The analysis, which examined 37 of trials involving thousands of participants, contrasted the outcomes of GLP-1 agonists with older methods.
Scientists point out that people who lose weight through lifestyle changes alone typically experience a less rapid weight regain—approximately 100 grams monthly—post-intervention.
Understanding the Fast Regain
Experts propose the mechanism of the injections explains the heightened weight return.
These medications copy a natural hormone called glucagon-like peptide-1, which moderates appetite.
"Sustained high doses of GLP-1 concentrations far above than normal may cause the body to produce less of its endogenous GLP-1, and could lessen responsiveness to its effects," noted Dr. Adam Collins, a dietetics expert.
"Stopping of this medication means appetite is unsuppressed, making excessive eating a significant risk."
A Chronic Condition?
Health authorities suggest the jabs for individuals with obesity-related medical conditions, alongside recommended lifestyle changes.
Professionals say that, given the likelihood of weight regain, the therapy is often ongoing.
This opinion is supported by drug manufacturers, who note that the findings "emphasize the chronic nature of excess weight," akin to managing diseases like hypertension.
Patient Experiences
People who have discontinued the jabs report a intense resurgence of appetite.
"It felt as if something flipping and you become starving," said a patient.
This challenge is compounded if patients have not developed sustainable dietary or behavioural changes during treatment.
Growing Adoption
Survey data show that a significant number of people in the UK have tried these injections in the past year, with desire remaining high.
- Use is higher among women than males.
- The 40s and 50s demographic shows the highest level of interest.
- A large proportion obtain the medications through private prescriptions rather than public health services.
Ultimately, experts stress that while these medications are effective tools for weight loss, they are not a permanent solution and long-term success relies on ongoing behavioural changes.
